ECM
GBT

ETrade Capital Management’s Global Blood Therapeutics, Inc. GBT Stock Holding History

ETrade Capital Management’s Portfolio GBT Stock Details GBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-9,568
Closed -$503K – 851
2019
Q2 		$503K Buy
+9,568
New +$550K 0.01% 557

Other funds holding GBT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

ETrade Capital Management's GBT Position: Q3 2019 in Review

ETrade Capital Management sold out of Global Blood Therapeutics, Inc. (GBT) in Q3 2019, closing a stake of 9,568 shares — an estimated $503K sold.

ETrade Capital Management first reported a position in GBT in Q2 2019 and held it in 1 quarter. The position peaked at $503K in Q2 2019. 208 funds tracked by Wall St. Rank hold GBT as of Q3 2019.

  • ETrade Capital Management reported no remaining Global Blood Therapeutics, Inc. position as of Q3 2019 after selling out during the quarter.
  • ETrade Capital Management sold 9,568 Global Blood Therapeutics, Inc. shares in Q3 2019, an estimated $503K.
  • ETrade Capital Management first reported a position in Global Blood Therapeutics, Inc. in Q2 2019 and held it in 1 quarter.
  • ETrade Capital Management's Global Blood Therapeutics, Inc. position peaked at $503K in Q2 2019.
  • 208 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q3 2019.

Based on ETrade Capital Management's 13F filing for Q3 2019, filed 13 Nov 2019.